Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739397 · ClinicalTrials.gov registry record
Evaluation of the EpiGlare Tester for the Measurement of Glare-Induced Changes in BSCVA in Subjects With and Without Cataracts
A clinical trial of Cataract, sponsored by Epico.
- Completed
- Registry status
- 89
- Enrollment target
- 1
- Study location
NCT04739397: Completed study of Cataract, sponsored by Epico.
NCT04739397 is a study of Cataract that has completed, run by Epico. The registered enrollment target is 89 participants, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04739397, a study of Cataract, has completed, sponsored by Epico.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
The EpiGlare Tester will identify visual disability resulting from the glare experienced by subjects with cataracts in the glare-induced change in best spectacle corrected visual acuity (BSCVA).
Primary Outcome
Change in best spectacle corrected visual acuity (BSCVA) measurements before and after glare testing using the EpiGlare Tester as the glare source in patients with and without cataracts.
Conditions Studied
Interventions
- DEVICE Glare Testing
Study Locations (1)
Ohio
- The Eye Center of Columbus - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-06 |
What the finished NCT04739397 record still lists
NCT04739397 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which Glare Testing is the first listed.
NCT04739397 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04739397 about?
NCT04739397 is a clinical study titled "Evaluation of the EpiGlare Tester for the Measurement of Glare-Induced Changes in BSCVA in Subjects With and Without Cataracts". The EpiGlare Tester will identify visual disability resulting from the glare experienced by subjects with cataracts in the glare-induced change in best spectacle corrected visual acuity (BSCVA).
What is the current status of trial NCT04739397?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2011-11. Estimated completion is 2013-06.
What conditions does trial NCT04739397 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT04739397?
The interventions under investigation include: Glare Testing (DEVICE).
Who is sponsoring clinical trial NCT04739397?
This trial is sponsored by Epico, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04739397 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04739397's enrollment target sits among peer trials
89 43rd of 83 higher than 41 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
RECRUITING · Phase 1
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia